---
layout: post
title: "Identification, Assessment, and Control of Nitrosamine Drug Substance-Related Impurities in Human Drug Products; Establishment of a Public Docket; Request for Comments"
date: 2026-02-05 18:55:26 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-09526
original_published: 2023-05-04 00:00:00 +0000
significance: 8.00
---

# Identification, Assessment, and Control of Nitrosamine Drug Substance-Related Impurities in Human Drug Products; Establishment of a Public Docket; Request for Comments

**Published:** February 05, 2026 18:55 UTC
**Source:** Federal Register
**Original Published:** May 04, 2023 00:00 UTC
**Document Number:** 2023-09526

## Summary

The Food and Drug Administration (FDA, Agency, or we) is announcing the establishment of a docket to solicit public comments on the identification, assessment, and control of N-nitrosamine (nitrosamine) drug substance-related impurities (NDSRIs) that may be considered by the Agency in its regulation of these types of impurities in drug products. This notice identifies scientific and regulatory considerations regarding the identification, assessment, and control of NDSRIs, including areas that may benefit from collaborative efforts, and requests comments on these topics. This notice is not intended to communicate FDA's regulatory expectations on these issues but is instead intended to seek input from the public to inform scientific and/or regulatory approaches as appropriate.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/05/04/2023-09526/identification-assessment-and-control-of-nitrosamine-drug-substance-related-impurities-in-human-drug)
- API: https://www.federalregister.gov/api/v1/documents/2023-09526

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
